Last mentioned: 4d ago
Cure Announcement
Medical officials formally announce the patient is cured, marking a global first for gene editing technology.
Six-Month Follow-up
Clinical evaluations confirm significant biological markers of recovery and the absence of off-target effects.
Therapy Administration
A one-time gene editing intervention is administered at a specialized pediatric facility in British Columbia.
Trial Enrollment
The B.C. teen is enrolled in a world-first experimental gene editing clinical trial for a rare genetic disorder.
ARK Invest, led by Cathie Wood, has significantly increased its position in CRISPR Therapeutics (CRSP), signaling continued high conviction in the gene-editing pioneer despite recent market fluctuations. This move highlights Wood's strategy of doubling down on disruptive genomic technologies during periods of valuation compression.
A British Columbia teenager has achieved a historic medical milestone, becoming the first person globally to be cured of a rare genetic disease using advanced gene editing technology. This breakthrough marks a definitive shift in the treatment of rare disorders, moving from chronic management to a potential one-time curative intervention.